Study the Response of Qurevo (Ombitasvir, Paritaprevir and Ritonavir) in End Stage Renal Disease Patients with Hepatitis C Virus

Abstract

According to the WHO there are 185 million people infected with HCV in the world. Egypt has the highest prevalence of hepatitis C virus (HCV) in the world reaching 13% equating to an estimated 12 million Egyptians . HCV is one of the main causes of liver cirrhosis and hepatocellular carcinoma. HCV can develop kidney disease because of extrahepatic manifestations of HCV or as a disease process independent of the HCV infection.In addition, hemodialysis has been a risk factor for acquiring HCV infection. The prevalence of HCV infection is high in patients with ESRD, on hemodialysis ranges from 6% to 60% in different parts of the world. Several studies show that patients on hemodialysis have an increased overall mortality risk if they have chronic HCV when compared with those on dialysis who do not have HCV. Antiviral treatment in CKD patients can be complicated because many of the agents used for anti-HCV therapy can accumulate to toxic levels in the setting of renal impairment. Treatment of HCV compensated cirrhosis with the new DAA therapy Qurevo “ombitasvir/ paritaprevir/ritonavir” with ribavirin in ESRD was approved in many countries. Based on that, the current study was conducted aiming to evaluate the efficacy and safety of Qurevo /Ribavirin regimen in ESRD Egyptian patients on regular hemodialysis who are infected with hepatitis C virus (HCV) . 50 ESRD patients on regular hemodialysis with a mean age of 51.4 years ,range from 23-77 years, 25 (50%) males, 25(50% females) were enrolled in a prospective cohort study. The study took place at the hepatic virology clinic at Ain Shams University hospital over a period of 15 months( from December 2016 to February 2018) .